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ABSTRACT
Celiac disease is an autoimmune disease that causes damage to the small intestine as a
result of ingesting gluten. Approximately 1% of the U.S population has it, but individuals
have a higher chance of getting the disease if they have the DQ2 gene or certain health
problems. The ingestion of gluten or being on a gluten free diet can also cause additional
health problems in the individual because they do not get enough vitamins and nutrients.
Since a gluten free diet is not always effective, other treatments options are currently
being researched including immunotherapy and modified wheat. This review will focus
on genetic and health susceptibility factors in order to diagnose individuals sooner and
to find more effective treatments. The implication of this new data can increase the
quality of life in those affected by the disease.
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INTRODUCTION
Celiac disease (CD) is an autoimmune disease characterized by an immune response to
gluten in the small intestine.(1) CD is prevalent in 0.5-1% of the population.(1) It is
associated with an individual’s genetic makeup(1) and specific health problems they may
have.(2) Certain individuals are more likely to develop celiac disease due to genetic
variation in the major histocompatibility complex (MHC) region.(3) However, this known
genetic influence is not enough to explain disease development.(3-5) Individuals with
celiac disease have an increased risk of reproductive abnormalities, impaired bone
health, cardiovascular and autoimmune diseases, and lymphoproliferative disorders
even if they follow a strict gluten free diet (GFD), the only known effective treatment for
CD.(2)
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Gluten is a protein found in wheat, barely, and rye which are most often found in bread,
pasta, baked goods and certain alcohols such as beer. In addition, it can be found in
toothpastes, lip balms, hair and skin products, medicines, and supplements. Therefore,
following a GFD can be challenging, but it allows recovery of the small intestine,
specifically the villi, which absorbs nutrients. Because of this recovery, a GFD also helps
lessen the severity of health problems present at diagnoses. This review will focus on the
genetic influence on the disease, health issues related to both the disease and its
treatment, and current research on alternative treatment methods.

GENETIC INFLUENCE
Celiac disease is a genetically susceptible disease. There are several known genes and
gene combinations that increase an individual’s likelihood of getting the disease. The
human leukocyte antigen (HLA) complex, a version of the major histocompatibility
complex (MHC), is a group of proteins that help the immune system differentiate
between the body’s proteins and foreign proteins.(6) The MHC class II genes are HLADPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1.(6) Thus far the
HLA-DQA1 and HLA-DQB1 genes have been found to have the strongest effect within
the MHC region on the development of the disease.(3) Individuals with CD have a 95%
probability of having a DQA1 gene and a 98% probability of having a DQB1 gene(4).
These account for about 23% of the heritability risk.(3)
Each MHC class II gene can have different allele variations and each variation is given a
specific number.(6) The variants HLA-DQA1*05:01 or HLA-DQA1*05:05 bind to HLADQB1*02:01 or HLA-DQB1*02:02 to form HLA-DQ2, and the variants HLA-DQA1*03:01
or HLA-DQA1*03:02 bind to HLA-DQB1*03:02 to form HLA-DQ8.(6) Individuals with CD
have a 93% probability of having a DQ2 gene.(4) In addition, individuals with the HLA
molecule DQ2.5, an isoform of DQ2, are at a high risk of getting CD(7) and those who are
homozygous for the haplotype DQ2 are diagnosed at a younger age.(8) Five independent
variants in the MHC region (not in the HLA-DQ genes) and 57 independent singlenucleotide polymorphism (SNPs) outside the MHC region are associated with celiac
disease risk.(3)
Specifically, the SNP’s rs11100722 and rs4956400 from the interleukin (IL)- 15 gene were
found to be associated to CD.(9) There is also a connection between the IL15RA
genotype and if an individual is diagnosed as a child or an adult.(9) Not only do genes
play a role in the susceptibility of an individual to CD, they also play a role in when the
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individuals will get the disease. Thus, understanding the genetic background of the
disease can allow for an earlier diagnosis.

HEALTH ISSUES
All CD Individuals
Since gluten exposure in CD damages the villi in their small intestine, they do not always
get the amount of nutrients they need. Because of this, these individuals compared to
the general population have an increase in mortality rate with malignancies, vascular
disease and respiratory disease being the most common cause of death.(10, 11) This
difference in mortality rate lessens as time from CD diagnosis increases.(10) In addition,
individuals with CD are generally at a higher risk of getting any lymphoproliferative
disease and small-intestinal lymphomas.(12) Furthermore, they are at an increased risk
of myocardial infection, angina pectoris, and stroke even though they do not have the
typical cardiovascular risk factors.(13) Since they do not have these typical risk factors
the diagnosis and treatment of these other health problems may prove to be more
difficult to determine and thus more damage to the body will happen.

Presence vs Absence of Gastrointestinal Symptoms
Individuals with CD are typically placed into two groups: those with gastrointestinal
symptoms or those without gastrointestinal symptoms. It is important to study both
groups as there is a delay in diagnosis between them. Individuals without gastrointestinal
symptoms have a delay of 42 months from their first doctors visit to their diagnosis from
biopsy compared to those who have the symptoms who usually have a delay of 2.3
months.(14) Individuals with thyroid abnormalities, other autoimmune diseases,
anemia, bone mineral density loss and lower ferritin and cholesterol levels have a higher
chance of having undiagnosed celiac disease and should be screened for the disease.(14,
15) These are not symptoms of CD, but they can be associated with the disease. Thus, a
simple blood analysis for antibodies and/or genetic factors may give an early diagnosis.
The prolonged exposure to gluten before diagnosis will cause more damage to the body
than if they had been diagnosed sooner. Thus, individuals who do not have the typical
gastrointestinal symptoms are more likely to have anemia (69.4% compared to 21.2%),
low bone mineral density (68% compared to 41%) and abnormal thyroid-stimulating
hormone (43.2% compared to 15.5%) with hypothyroidism being more common than
hyperthyroidism.(14)
13

Gluten Free Diet
A gluten free diet is the only current treatment for CD, yet 30% of affected individuals
still have symptoms(16) which can be limiting to the person’s life. A study done in Italy
on 13-18 year old’s found 30.8% avoided restaurants most or all of the time and 7.9%
avoided traveling most or all of the time.(17) Either gluten free foods and items need to
be more prominent and accessible so people do not feel limited or an alternative
treatment must be created that allowed CD individuals to consume gluten without
harming themselves. 92.1% brought gluten-free food while traveling(17) because gluten
free food can be hard to find in some locations. Having this unnecessary stress of where
and what they can eat and feelings of isolation from missing out can be harmful to the
individual. In fact, a GFD may cause mental or emotional problems in addition to physical
problems. A study found that all CD individuals with mucosal healing had a higher risk of
getting anxiety compared to CD individuals with continuous villous atrophy, and CD
women with mucosal healing had a higher risk of getting depression compared to CD
women who had continuous villous atrophy.(18) Their small intestine and therefore
digestion was improving but avoiding the items with gluten and their vigilance to the
GFD was mentally harmful.

ALTERNATIVE TREATMENTS
While a gluten free diet is the only current treatment for celiac disease, it is not always
the most effective. Certain situations can make it hard for an individual to have access to
gluten free food, certain foods labeled gluten free may be contaminated,(19) and
individuals who do not get enough nutrients and minerals from their GFD are at a higher
risk of health problems.(2) Because of this, many studies are investigating alternative
treatments. A peptide-based, epitope-specific immunotherapy called Nexvax2 was used
in a phase 1 study that investigated the effect of varying starting dosages and maximum
dosages on villus recovery.(20) A starting dose of 3 μg and a maintenance dose of 300 μg
had the least amount of drug related adverse events with only 20% of those events being
graded at least moderate to severe(20) (Table 1). This drug is supposed to increase an
individual’s tolerance of gluten which will eventually allow them to consume gluten again
without the damage it originally caused. Therefore, it will also lessen health issues
associated with CD providing better quality of life to affected individuals. Participants
were separated into two cohorts which may explain differences in effectiveness: cohort

14

1 were those who are homozygous for HLA-DQ2.5 and cohort 2 were those who are nonhomozygous.(20)
Studying the immune system, specifically the characteristics that the body is having an
immune response, is important in celiac disease treatments because it proves whether
the treatment is effective. For instance, the presence of the antibodies antitransglutaminase (anti-tTG) and endomysium (EMA) after ingesting gluten means the
body is having an immune response. A study found individuals getting microbial
transglutaminase (mTG) -modified wheat flour are less likely to have positive serum antitTG and EMA antibodies results and less likely to have intestinal villous atrophy because
there is less or no immune response to gluten.(21) Individuals ingesting the unmodified
flour had more severe bloating, nausea and abdominal pain and swelling.(21) Therefore,
the modified flour seems safer than the unmodified, but approximately 25% of the
individuals consuming modified flour still had disease activity following the trial(21)
(Table 1). Larger and longer studies with more palatable food should be done to get a
better understanding on the affect mTG modified wheat flour has on CD individuals.(21)
Another study is investigating the affect oligofructose-enriched inulin, a type of prebiotic
referred to as Synergy 1, on intestinal microbiota in children with CD.(22) There were
only a few episodes of side effects where were fairly equal between the treatment and
placebo groups.(22) The kids getting Synergy 1 had normal stools more often than the
children getting the placebo (Table 1) and one child even had alleviation of CD symptoms
that were present before the trial while taking Synergy 1.(22)

CONCLUSION
Celiac disease affects 0.5%-1% of the global population putting them at risk for other
health issues and the only treatment is to avoid the consumption of gluten.(1) This
treatment is not the most effective as it may be hard for individuals to follow this in
certain situations, they may ingest contaminated food, they may continue to have
symptoms, or they may feel isolated.(16, 17, 19) In addition, not everyone has the same
symptoms,(14) so some people continue eating gluten even though it is damaging their
intestine. It is important to study this disease because misdiagnoses, no diagnoses, or
the lack of other treatments can increase chances of certain health problems and
mortality. In addition, understanding the influence of specific genes on the disease can
help find better treatments and allow for earlier diagnosis.(9) Additionally, broader
studies should be done to find specific immunotherapy drugs that improve gluten
tolerance without causing any adverse events for all individuals with celiac disease. An
improved tolerance would allow individuals with CD to have more freedom in where and
15

what they eat and where they travel which would improve the affected individual’s
quality of life.

Table 1: The side effects and effectiveness of potential treatments for celiac disease
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